Search

Your search keyword '"Michel, Martin C."' showing total 3,058 results
Start Over Author "Michel, Martin C."
3,058 results on '"Michel, Martin C."'

3. Project-Based Public–Private Collaborations

Author

Hein, Peter, Michel, Martin C., Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Series Editor, Seifert, Roland, Editorial Board Member, Wang, KeWei, Editorial Board Member, and Wieland, Heike A., editor

Published
2024
Full Text
View/download PDF

4. Adrenoceptor Expression and Function in the Endocrine Pancreas

Author

Dwaib, Haneen, Michel, Martin C., Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Editorial Board Member, Seifert, Roland, Editorial Board Member, Wang, KeWei, Editorial Board Member, Baker, Jillian G., editor, and Summers, Roger J., editor

Published
2024
Full Text
View/download PDF

5. Introduction: A Short History of Adrenoceptor Research

Author

Michel, Martin C., Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Editorial Board Member, Seifert, Roland, Editorial Board Member, Wang, KeWei, Editorial Board Member, Baker, Jillian G., editor, and Summers, Roger J., editor

Published
2024
Full Text
View/download PDF

6. Adrenoceptors in the Lower Urinary Tract

Author

Hennenberg, Martin, Michel, Martin C., Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Editorial Board Member, Seifert, Roland, Editorial Board Member, Wang, KeWei, Editorial Board Member, Baker, Jillian G., editor, and Summers, Roger J., editor

Published
2024
Full Text
View/download PDF

7. From BPH to male LUTS: a 20-year journey of the EAU guidelines

Author

Gravas, Stavros, Malde, Sachin, Cornu, Jean-Nicolas, Gacci, Mauro, Gratzke, Christian, Herrmann, Thomas R. W., Karavitakis, Markos, Mamoulakis, Charalampos, Rieken, Malte, Sakalis, Vasileios I., Schouten, Natasha, Smith, Emma J., Speakman, Mark J., Tikkinen, Kari A. O., Alivizatos, Gerasimos, Bach, Thorsten, Bachmann, Alexander, Descazeaud, Aurelian, Desgrandchamps, François, Drake, Marcus, Emberton, Mark, Kyriazis, Iason, Madersbacher, Stephan, Michel, Martin C., N’Dow, James, Perachino, Massimo, Plass, Karin, Rioja Sanz, Carlos, Umbach, Roland, de Wildt, Michel, Oelke, Matthias, and de la Rosette, Jean J. M. C. H.

Published
2024
Full Text
View/download PDF

10. Contributors

Author

Barnes, Peter J., primary, Behnisch, Robert, additional, Boura, Alan L.A., additional, Brocklehurst, Walter E., additional, Burg, Richard W., additional, Bush, Karen, additional, Christensen, Søren Brøgger, additional, Collier, Harry O.J., additional, Ennis, Madeleine, additional, Flower, Roderick J., additional, Green, Alan F., additional, Lorenz, Wilfried, additional, McGrath, John Christie, additional, Michel, Martin C., additional, Moser, Heinz, additional, Rainsford, Kim D., additional, Selwyn, Sydney, additional, Shanks, Robert G., additional, Shen, T.Y., additional, Tiligada, Katerina, additional, and Woodruff,, H. Boyd, additional

Published
2024
Full Text
View/download PDF

11. Sex and Gender Differences in the Pharmacology of the Overactive Urinary Bladder

Author

Pautz, Andrea, Michel, Martin C., Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Editorial Board Member, Wang, KeWei, Editorial Board Member, Tsirka, Stella E., editor, and Acosta-Martinez, Maricedes, editor

Published
2023
Full Text
View/download PDF

24. Building Robustness into Translational Research

Author

Erdogan, Betül R., Michel, Martin C., Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Rosenthal, Walter, Editorial Board Member, Wang, KeWei, Editorial Board Member, Bespalov, Anton, editor, and Steckler, Thomas, editor

Published
2020
Full Text
View/download PDF

28. Perspectives of Pharmacology over the Past 100 Years

Author

Barrett, James E., Page, Clive, Michel, Martin C., Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Rosenthal, Walter, Editorial Board Member, and Wang, KeWei, Editorial Board Member

Published
2019
Full Text
View/download PDF

29. Why Are New Drugs Expensive and How Can They Stay Affordable?

Author

Hammel, Basma, Michel, Martin C., Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Rosenthal, Walter, Editorial Board Member, and Wang, KeWei, Editorial Board Member

Published
2019
Full Text
View/download PDF

37. Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes.

Author

Erdogan, Betul R., Yesilyurt-Dirican, Zeynep E., Karaomerlioglu, Irem, Muderrisoglu, Ayhanim Elif, Sevim, Kadir, Michel, Martin C., and Arioglu-Inan, Ebru

Subjects
SPRAGUE Dawley rats, LABORATORY rats, TYPE 2 diabetes, ANGIOTENSIN receptors, ENTRESTO
Abstract

Cardiovascular complications are the major cause of diabetes mellitus-related morbidity and mortality. Increased renin–angiotensin–aldosterone system activity and decreased β-adrenergic receptor (β-AR) responsiveness contribute to diabetic cardiac dysfunction. We evaluated the effect of sacubitril/valsartan (neprilysin inhibitor plus angiotensin receptor antagonist combination) and valsartan treatments on the diabetic cardiac function through β-AR responsiveness and on protein expression of diastolic components. Six-week-old male Sprague Dawley rats were divided into control, diabetic, sacubitril/valsartan (68 mg/kg)-, and valsartan-treated (31 mg/kg) diabetic groups. Diabetes was induced by a high-fat diet plus low-dose streptozotocin (30 mg/kg, intraperitoneal). After 10 weeks of diabetes, rats were treated for 4 weeks. Systolic/diastolic function was assessed by in vivo echocardiography and pressure–volume loop analysis. β-AR-mediated responsiveness was assessed by in vitro papillary muscle and Langendorff heart experiments. Protein expression of sarcoplasmic reticulum calcium ATPase2a, phospholamban, and phosphorylated phospholamban was determined by Western blot. Sacubitril/valsartan improved ejection fraction and fractional shortening to a similar extent as valsartan alone. None of the treatments affected in vivo diastolic parameters or the expression of related proteins. β1-/β2-AR-mediated responsiveness was partially restored in treated animals. β3-AR-mediated cardiac relaxation (an indicator of diastolic function) responses were comparable among groups. The beneficial effect of sacubitril/valsartan on systolic function may be attributed to improved β1-/β2-AR responsiveness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Effects of a proprietary mixture of extracts from Sabal serrulata fruits and Urtica dioica roots (WS® 1541) on prostate hyperplasia and inflammation in rats and human cells

Author

Sens-Albert, Carla, primary, Weisenburger, Sabrina, additional, König, Beatrix C., additional, Melcher, Silas F., additional, Scheyhing, Ulrike A. M., additional, Rollet, Karin, additional, Lluel, Philippe, additional, Koch, Egon, additional, Lehner, Martin D., additional, and Michel, Martin C., additional

Published
2024
Full Text
View/download PDF

46. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans

Author

Michel, Martin C, Mayoux, Eric, and Vallon, Volker

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Kidney Disease, Nutrition, Diabetes, Obesity, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Cardiovascular, Renal and urogenital, Metabolic and endocrine, Animals, Benzhydryl Compounds, Diabetes Mellitus, Glucose, Glucosides, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Type 2 diabetes mellitus, Empagliflozin, diabetic nephropathy, endothelial dysfunction, blood pressure, Medical Physiology, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences
Abstract

Empagliflozin (formerly known as BI 10773) is a potent, competitive, and selective inhibitor of the sodium glucose transporter SGLT2, which mediates glucose reabsorption in the early proximal tubule and most of the glucose reabsorption by the kidney, overall. Accordingly, empagliflozin treatment increased urinary glucose excretion. This has been observed across multiple species including humans and was reported under euglycemic conditions, in obesity and, most importantly, in type 2 diabetic patients and multiple animal models of type 2 diabetes and of type 1 diabetes. This led to a reduction in blood glucose, smaller blood glucose excursions during oral glucose tolerance tests, and, upon chronic treatment, a reduction in HbA1c in animal models and patients. In rodents, such effects were observed in early and late phases of experimental diabetes and were associated with preservation of pancreatic β-cell function. Combination studies in animals demonstrated that beneficial metabolic effects of empagliflozin may also manifest when added to other types of anti-hyperglycemic treatments including linagliptin and pioglitazone. While some anti-hyperglycemic drugs lead to weight gain, empagliflozin treatment was associated with reduced body weight in normoglycemic obese and non-obese animals despite an increased food intake, largely due to a loss of adipose tissue; on the other hand, empagliflozin preserved body weight in models of type 1 diabetes. Empagliflozin improved endothelial dysfunction in diabetic rats and arterial stiffness, reduced blood pressure in diabetic patients, and attenuated early signs of nephropathy in diabetic animal models. Taken together, the SGLT2 inhibitor empagliflozin improves glucose metabolism by enhancing urinary glucose excretion; upon chronic administration, at least in animal models, the reductions in blood glucose levels are associated with beneficial effects on cardiovascular and renal complications of diabetes.

Published
2015

50. Adrenoceptors in GtoPdb v.2023.3

Author

Baker, Jillian G., primary, Balaji, Poornima, primary, Bond, Richard A., primary, Bylund, David B., primary, Eikenburg, Douglas C., primary, Graham, Robert M., primary, Hieble, J. Paul, primary, Hills, Rebecca, primary, Michel, Martin C., primary, Minneman, Kenneth P., primary, Parra, Sergio, primary, Perez, Dianne, primary, and Summers, Roger, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results